Amphastar Pharmaceuticals, Inc.AMPHNASDAQ
LOADING
|||
EPS Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
-42.42%
↓ 121% below average
Average (39q)
201.67%
Historical baseline
Range
High:4950.00%
Low:-633.33%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -42.42% |
| Q2 2025 | 24.53% |
| Q1 2025 | -32.05% |
| Q4 2024 | -6.02% |
| Q3 2024 | 6.41% |
| Q2 2024 | -13.33% |
| Q1 2024 | 20.00% |
| Q4 2023 | -25.74% |
| Q3 2023 | 87.04% |
| Q2 2023 | 0.00% |
| Q1 2023 | -22.86% |
| Q4 2022 | 118.75% |
| Q3 2022 | -8.57% |
| Q2 2022 | -30.00% |
| Q1 2022 | 21.95% |
| Q4 2021 | -33.87% |
| Q3 2021 | 287.50% |
| Q2 2021 | 45.45% |
| Q1 2021 | 184.62% |
| Q4 2020 | -262.50% |
| Q3 2020 | 2051.22% |
| Q2 2020 | -104.56% |
| Q1 2020 | 510.96% |
| Q4 2019 | -173.00% |
| Q3 2019 | -97.03% |
| Q2 2019 | 4950.00% |
| Q1 2019 | -50.00% |
| Q4 2018 | -20.00% |
| Q3 2018 | 183.47% |
| Q2 2018 | 62.56% |
| Q1 2018 | -633.33% |
| Q4 2017 | 689.47% |
| Q3 2017 | -90.50% |
| Q2 2017 | 100.00% |
| Q1 2017 | 133.61% |
| Q4 2016 | -166.11% |
| Q3 2016 | -40.00% |
| Q2 2016 | 150.00% |
| Q1 2016 | -64.71% |
| Q4 2015 | 356.02% |